|
Skyepharma is to sell its injectable drugs business to Blue Acquisition for up to £42m, in order to focus on its Flutiform asthma treatment, and has also announced plans to raise £15m in a share placing. 10-Jan-2007 Skyepharma is planning to relocate its London headquarters from Piccadilly to a less expensive area, in order to cut costs. 21-Feb-2006 Skyepharma, the pharmaceutical reformulation company, has received a takeover approach from an unnamed company. 15-Nov-2005 Skyepharma is to raise £35m in a rights issue to fund the development of its Flutiform asthma drug. 29-Sep-2005 Skyepharma has invested £2.5m in Micap of Newton-le-Willows, in order to investigate the pharmaceutical applications of Micap's micro-encapsulation technology. 16-Jan-2003 Skyepharma has raised £15m from the sale of the European distribution rights of the Solaraze skin treatment to Shire Pharmaceuticals, and has also announced a £25m investment from Kowa of Japan. 14-May-2002 Skyepharma has acquired the remaining 60% of RTP Pharma of Canada for £14m, and has raised £20m of development funding from Paul Capital Royalty Acquisition Fund. 14-Mar-2002 Skyepharma is to pay £18m for a 40% stake in RTP Pharma, the Canadian drug delivery company that has developed new technology for improving the solubility of substances. 01-Aug-2001 Skyepharma is to receive a £20m equity investment from Paul Capital Partners of the US to fund clinical trials of a new painkiller drug. 10-Jan-2001 Skyepharma is to raise £60m through a convertible bond in order to fund the development of its own drugs, having decided to change its strategy away from developing products for other companies. 18-May-2000 Skyepharma is forming a joint venture with PA Consulting to develop a new asthma inhaler. 27-Mar-2000 Skyepharma is to develop a controlled release version of the Requip treatment for Parkinson's disease, in a £5m alliance with SmithKline Beecham. 14-Sep-1999 Skyepharma is acquiring Hyal Pharmaceutical Corporation of Canada for £3.8m. 20-May-1999 Skyepharma has won US approval for an oral controlled release version of SmithKline Beecham's anti-depressant Paxil. 19-Feb-1999 Novartis of Switzerland has acquired a 2% stake in Skyepharma in a £6m deal that will give it access to the UK company's dry powder inhaler technology. 18-Nov-1998 Skyepharma is planning to acquire DepoTech, the US biotechnology concern, for up to £33m. 20-Oct-1998 Skyepharma is to collaborate with Sepracor of the US to develop a new treatment for asthma. 10-Oct-1998 Skyepharma is discussing the possible acquisition of companies and products in the US drug delivery sector, as it believes that they are currently undervalued. 03-Sep-1998 Skyepharma has raised £22m in a share placing in order to fund the acquisition of new drug technologies. 18-Jul-1998 Skyepharma is to raise up to £31m in a share offering on Nasdaq in order to expand its drugs R&D programme and to benefit from the higher rating it expects its shares to receive in the US. 04-Jun-1998 Skyepharma is considering plans to raise its profile with US investors through a share placing of about £15m, and would use the proceeds to acquire companies to increase its range of drug delivery methods. 15-Apr-1998 Skyepharma is planning to list its shares in New York by July, and has also announced a deal with Astra of Sweden to develop new drug formulations. 13-Mar-1998 Skyepharma has announced that the US FDA is to consider an application for the launch of a new slow-release formulation for its Paxil anti-depressant. 25-Feb-1998 Skyepharma has raised about £10m in a debentures placing in the US, which will enable it to complete a French factory and fund its drugs development programme until March 1999. 17-Feb-1998 Skyepharma, the biotechnology company, has raised £7.4m from a share placing but says it now needs to raise more cash to help fund it into profit, following delays in drug development. 13-Sep-1997 Skyepharma has announced a licensing deal in which Abbott Laboratories of the US will use its geomatrix slow-release drug delivery technique to produce the asthma drug Zileuton. 21-Jan-1997 Skyepharma plans to raise £140m on the market to acquire Jago Holdings, the Swiss drug delivery concern. 19-Mar-1996
|